Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Nirali N ShahDaniel W LeeBonnie YatesConstance M YuanHaneen ShalabiStaci MartinPamela L WoltersSeth M SteinbergEva H BakerCindy P DelbrookMaryalice Stetler-StevensonTerry J FryDavid F StroncekCrystal L MackallPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
We provide the longest follow-up in CAYAs with B-ALL after CD19-CAR T-cell therapy reported to date and demonstrate that sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT can mediate durable disease control in a sizable fraction of CAYAs with relapsed or refractory B-ALL (ClinicalTrials.gov identifier: NCT01593696).